Cambridge is a technological ecosystem at the forefront of technological innovation, with our city centre office taking care of IP logistics for a number of sizeable firms as well as local start-ups. A new series of articles produced by M&C talent will go further into the history - and future - of this great city.
The European Patent Office (EPO) has seen a remarkable increase in the number of AI patent filings in the Agritech sector in recent years. In this article we highlight the growth from the year 2000 until 2019.
Augmented and virtual reality technologies are helping the biopharma industry to access remote teams and educational tools, as well as giving the workforce the opportunity to collaborate virtually and safely. Our panel discussion reflects on the impact of using these technologies for training in Life Sciences, including the regulatory and legal considerations.
Bill C-27, the Digital Charter Implementation Act, 2022 (DICA) was introduced on June 16, proposing to enact three pieces of legislation aimed at strengthening the private sector privacy framework in Canada.
Wind power will undoubtedly be a significant part of the energy mix of the future. Protecting and future proofing the technical advancements of today will ensure that wind power is efficient and high value for all involved.
Scotland has a thriving Medical Technology (MedTech) industry, with over 250 companies, and approximately 9,000 people employed in this sector. Many of these businesses have Artificial Intelligence (AI) powering them, as AI’s ability to analyse large swathes of data in a matter of moments enables faster diagnosis and improved patient outcomes.
New and innovative AI is potentially patentable, at least in the UK and Europe, as long as it is either specifically applied to a given technical application (applied AI) or is specifically adapted to the technical features of the system on which it is run.
In a lengthy and complex decision reaching over 80 pages and one that will be welcomed by holders of standard essential patents (SEPs), Mr Justice Meade has given judgment in the latest in a series of trials in the UK’s Patents Court between Optis and Apple concerning Optis’ SEPs and the FRAND obligations which apply to them. Two previous trials had established that two of Optis’ SEPs were valid, essential and infringed. One of those patents had expired, the other had not. A trial is due to take place in June 2022 (“Trial E”), at which the court will decide what the terms of a global FRAND licence should be and whether Optis’ approach to the negotiations with Apple breached competition law.